Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and…
Read More
Categories
- angelMD, Inc.
- Arbor Rapha Capital BioHoldings Corp I
- Asclepix Therapeutics, Inc.
- Bellicum Pharmaceuticals, Inc.
- DELiver Therapeutics
- Eos SENOLYTIX
- Events
- FIZE Medical Ltd
- IMAGIN Medical
- K2 Biolabs
- News
- NexImmune, Inc.
- NuMat Technologies, Inc.
- Past Events
- Perseus SENOLYTIX
- Phoenix SENOLYTIX
- Ponce Aurora
- Portfolio
- Poseida Therapeutics, Inc.
- Press Releases
- PrintBio, Inc.
- Rapha Capital Management
- SENOTHERAPEUTIX
- Sightly Enterprises, Inc.
Archives
- April 2026
- March 2026
- February 2026
- September 2025
- February 2025
- January 2025
- July 2023
- December 2022
- October 2022
- August 2022
- June 2022
- December 2021
- November 2021
- October 2021
- August 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- June 2020
- May 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- July 2018
- April 2018
- January 2018
- July 2017
